Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Press Releases Year None202220212020 Sep 12, 2022 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants Sep 12, 2022 Adagio Therapeutics Announces Corporate Name Change to Invivyd Sep 06, 2022 Adagio Therapeutics to Participate in Upcoming Investor Conferences Aug 15, 2022 Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights Jul 05, 2022 Adagio Announces David Hering Named Permanent Chief Executive Officer and Director Jul 01, 2022 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors May 13, 2022 Adagio Therapeutics Reports First Quarter 2022 Financial Results Apr 14, 2022 Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request Mar 30, 2022 Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization Mar 18, 2022 Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 15
Year None202220212020 Sep 12, 2022 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants Sep 12, 2022 Adagio Therapeutics Announces Corporate Name Change to Invivyd Sep 06, 2022 Adagio Therapeutics to Participate in Upcoming Investor Conferences Aug 15, 2022 Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights Jul 05, 2022 Adagio Announces David Hering Named Permanent Chief Executive Officer and Director Jul 01, 2022 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors May 13, 2022 Adagio Therapeutics Reports First Quarter 2022 Financial Results Apr 14, 2022 Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request Mar 30, 2022 Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization Mar 18, 2022 Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 15
Sep 12, 2022 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
Aug 15, 2022 Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Jul 01, 2022 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
Mar 30, 2022 Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
